New Zealand markets closed

Amylyx Pharmaceuticals, Inc. (AMLX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7550-0.1350 (-7.14%)
At close: 04:00PM EDT
1.7798 +0.02 (+1.41%)
After hours: 07:54PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-184,015
49,271
-198,375
-87,931
-42,280
Depreciation & amortisation
327
1,088
487
52
1
Stock-based compensation
16,714
37,161
21,714
3,136
243
Change in working capital
8,654
-65,661
-1,641
4,595
2,599
Accounts receivable
-2,797
-24,744
-15,306
0
-
Inventory
-69,079
-73,129
-9,769
0
-
Accounts payable
4,040
15,882
1,854
670
1,418
Other working capital
-160,510
10,678
-182,397
-75,152
-36,848
Other non-cash items
-
-
-
5,228
1,738
Net cash provided by operating activities
-158,418
11,919
-179,871
-74,799
-36,697
Cash flows from investing activities
Investments in property, plant and equipment
-2,092
-1,241
-2,526
-353
-151
Purchases of investments
-154,313
-300,826
-415,873
-49,053
0
Sales/maturities of investments
148,411
394,120
179,411
3,000
0
Net cash used for investing activities
-7,994
92,053
-238,988
-46,406
-151
Cash flows from financing activities
Debt repayment
-
0
0
-263
-
Common stock issued
-
0
432,447
0
-
Other financing activities
-2,674
-3,451
-2,847
-2,733
-
Net cash used provided by (used for) financing activities
198,562
3,543
431,789
158,506
46,823
Net change in cash
31,587
107,675
12,865
37,314
9,975
Cash at beginning of period
76,866
63,245
50,380
13,066
3,091
Cash at end of period
109,016
170,920
63,245
50,380
13,066
Free cash flow
Operating cash flow
-158,418
11,919
-179,871
-74,799
-36,697
Capital expenditure
-2,092
-1,241
-2,526
-353
-151
Free cash flow
-160,510
10,678
-182,397
-75,152
-36,848